Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post–CAR-T therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

AJAlexandria JensenDLDasom LeeAGAnmol Goyal

Discussion

Loading...

Member takes

Overview

Discovery cohort shows metabolic tumor volume identifies high-risk LBCL, indicating prognosis for CAR-T therapy.

Key Points

  • Establish a cutpoint for metabolic tumor volume to predict outcomes in relapsed/refractory large B cell lymphoma post-CAR-T.
  • Identified patients with R/R LBCL treated with CAR-T therapy from 2017-2024.
  • Baseline metabolic tumor volume was measured using PET-CT prior to apheresis.
  • Performed a log-rank statistic analysis for risk stratification based on MTV levels.
  • Identified a cutpoint of 125.5 mL for metabolic tumor volume during discovery and validation phases.
  • Patients with high MTV had worse median progression-free survival (4.2 months) compared to low MTV (36.3 months).
  • Toxicity-free progression-free survival rate at 12 months was 54% for the overall cohort.

Cite This Study

Jensen et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d736https://doi.org/10.1182/blood-2025-397
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell Therapy2026 · 1 citations
  2. 2Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell Therapy.2026
  3. 3Prognostic value of positron emission tomography-derived metabolic tumor volume for the efficacy of anti-CD19 CAR T-cell therapy in patients with relapsed/refractory non-Hodgkin lymphomas2025
  4. 4Prognosis prediction beyond MTV using easy to calculate parameters derived from FDG-PET/CT, a pilot Study2025
  5. 5Performance of radiomics features in patients with peripheral T-cell lymphoma: Data from international prospective T-cell project 2.02025